Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NATR's Cash to Debt is ranked higher than
99% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. NATR: No Debt )
NATR' s 10-Year Cash to Debt Range
Min: 1.41   Max: No Debt
Current: No Debt

Equity to Asset 0.63
NATR's Equity to Asset is ranked higher than
72% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. NATR: 0.63 )
NATR' s 10-Year Equity to Asset Range
Min: 0.31   Max: 0.73
Current: 0.63

0.31
0.73
Interest Coverage 104.14
NATR's Interest Coverage is ranked higher than
69% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.95 vs. NATR: 104.14 )
NATR' s 10-Year Interest Coverage Range
Min: 13.14   Max: 9999.99
Current: 104.14

13.14
9999.99
F-Score: 7
Z-Score: 4.85
M-Score: -2.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 4.79
NATR's Operating margin (%) is ranked higher than
67% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.59 vs. NATR: 4.79 )
NATR' s 10-Year Operating margin (%) Range
Min: 0.83   Max: 11.97
Current: 4.79

0.83
11.97
Net-margin (%) 4.14
NATR's Net-margin (%) is ranked higher than
68% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.31 vs. NATR: 4.14 )
NATR' s 10-Year Net-margin (%) Range
Min: -2.25   Max: 7.72
Current: 4.14

-2.25
7.72
ROE (%) 13.69
NATR's ROE (%) is ranked higher than
87% of the 874 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. NATR: 13.69 )
NATR' s 10-Year ROE (%) Range
Min: -12.81   Max: 33.07
Current: 13.69

-12.81
33.07
ROA (%) 7.78
NATR's ROA (%) is ranked higher than
85% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.02 vs. NATR: 7.78 )
NATR' s 10-Year ROA (%) Range
Min: -5.25   Max: 23.36
Current: 7.78

-5.25
23.36
ROC (Joel Greenblatt) (%) 41.92
NATR's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.17 vs. NATR: 41.92 )
NATR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 10.4   Max: 138.58
Current: 41.92

10.4
138.58
Revenue Growth (%) 1.00
NATR's Revenue Growth (%) is ranked higher than
65% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. NATR: 1.00 )
NATR' s 10-Year Revenue Growth (%) Range
Min: -2.3   Max: 20
Current: 1

-2.3
20
EBITDA Growth (%) 16.50
NATR's EBITDA Growth (%) is ranked higher than
82% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. NATR: 16.50 )
NATR' s 10-Year EBITDA Growth (%) Range
Min: -27.5   Max: 30
Current: 16.5

-27.5
30
EPS Growth (%) 25.60
NATR's EPS Growth (%) is ranked higher than
86% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. NATR: 25.60 )
NATR' s 10-Year EPS Growth (%) Range
Min: -29.3   Max: 55.9
Current: 25.6

-29.3
55.9
» NATR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

NATR Guru Trades in Q4 2013

Jim Simons 93,700 sh (+4.34%)
» More
Q1 2014

NATR Guru Trades in Q1 2014

Jim Simons 122,920 sh (+31.18%)
» More
Q2 2014

NATR Guru Trades in Q2 2014

Jim Simons 139,700 sh (+13.65%)
» More
Q3 2014

NATR Guru Trades in Q3 2014

Chuck Royce 1,700 sh (New)
Jim Simons 156,800 sh (+12.24%)
» More
» Details

Insider Trades

Latest Guru Trades with NATR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-03-31 Sold Out 0.04%$13.89 - $15.74 $ 15.092%0
Joel Greenblatt 2012-12-31 Add 20.16%0.01%$13.02 - $17.73 $ 15.09-4%44695
Joel Greenblatt 2012-09-30 Reduce -22.14%0.01%$14.09 - $16.91 $ 15.09-3%37195
Joel Greenblatt 2012-03-31 Add 33.91%0.02%$14.33 - $17.11 $ 15.092%46664
Joel Greenblatt 2011-12-31 Add 75.35%0.03%$12.5 - $18.25 $ 15.09-6%34848
Joel Greenblatt 2011-09-30 New Buy0.05%$14.33 - $20.31 $ 15.09-15%19873
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 15.90
NATR's P/E(ttm) is ranked higher than
93% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.00 vs. NATR: 15.90 )
NATR' s 10-Year P/E(ttm) Range
Min: 7.88   Max: 159.88
Current: 15.9

7.88
159.88
P/B 1.80
NATR's P/B is ranked higher than
84% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. NATR: 1.80 )
NATR' s 10-Year P/B Range
Min: 1.41   Max: 3.87
Current: 1.8

1.41
3.87
P/S 0.70
NATR's P/S is ranked higher than
95% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.96 vs. NATR: 0.70 )
NATR' s 10-Year P/S Range
Min: 0.21   Max: 1.96
Current: 0.7

0.21
1.96
EV-to-EBIT 11.78
NATR's EV-to-EBIT is ranked higher than
93% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.72 vs. NATR: 11.78 )
NATR' s 10-Year EV-to-EBIT Range
Min: 3.5   Max: 136.6
Current: 11.78

3.5
136.6
PEG 0.95
NATR's PEG is ranked higher than
95% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. NATR: 0.95 )
NATR' s 10-Year PEG Range
Min: 0.22   Max: 1.67
Current: 0.95

0.22
1.67
Shiller P/E 17.70
NATR's Shiller P/E is ranked higher than
94% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.40 vs. NATR: 17.70 )
NATR' s 10-Year Shiller P/E Range
Min: 8.59   Max: 180.1
Current: 17.7

8.59
180.1
Current Ratio 2.33
NATR's Current Ratio is ranked higher than
70% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. NATR: 2.33 )
NATR' s 10-Year Current Ratio Range
Min: 1.32   Max: 2.48
Current: 2.33

1.32
2.48
Quick Ratio 1.64
NATR's Quick Ratio is ranked higher than
68% of the 890 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. NATR: 1.64 )
NATR' s 10-Year Quick Ratio Range
Min: 0.83   Max: 1.79
Current: 1.64

0.83
1.79

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.70
NATR's Dividend Yield is ranked higher than
81% of the 518 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. NATR: 2.70 )
NATR' s 10-Year Dividend Yield Range
Min: 0.3   Max: 4.04
Current: 2.7

0.3
4.04
Dividend Payout 0.43
NATR's Dividend Payout is ranked higher than
75% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. NATR: 0.43 )
NATR' s 10-Year Dividend Payout Range
Min: 0.1   Max: 1.67
Current: 0.43

0.1
1.67
Yield on cost (5-Year) 2.70
NATR's Yield on cost (5-Year) is ranked higher than
76% of the 527 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.46 vs. NATR: 2.70 )
NATR' s 10-Year Yield on cost (5-Year) Range
Min: 0.3   Max: 4.04
Current: 2.7

0.3
4.04
Share Buyback Rate -1.60
NATR's Share Buyback Rate is ranked higher than
75% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -1.50 vs. NATR: -1.60 )
NATR' s 10-Year Share Buyback Rate Range
Min: 5.5   Max: -2.7
Current: -1.6

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 10.48
NATR's Price/Net Current Asset Value is ranked higher than
87% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. NATR: 10.48 )
NATR' s 10-Year Price/Net Current Asset Value Range
Min: 6.51   Max: 78.11
Current: 10.48

6.51
78.11
Price/Tangible Book 1.85
NATR's Price/Tangible Book is ranked higher than
88% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. NATR: 1.85 )
NATR' s 10-Year Price/Tangible Book Range
Min: 1.49   Max: 10.64
Current: 1.85

1.49
10.64
Price/DCF (Projected) 1.53
NATR's Price/DCF (Projected) is ranked higher than
90% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.00 vs. NATR: 1.53 )
NATR' s 10-Year Price/DCF (Projected) Range
Min: 0.41   Max: 2.09
Current: 1.53

0.41
2.09
Price/Median PS Value 1.02
NATR's Price/Median PS Value is ranked higher than
82% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.33 vs. NATR: 1.02 )
NATR' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 3.47
Current: 1.02

0.36
3.47
Price/Peter Lynch Fair Value 1.62
NATR's Price/Peter Lynch Fair Value is ranked higher than
93% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. NATR: 1.62 )
NATR' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.34   Max: 2.03
Current: 1.62

0.34
2.03
Price/Graham Number 1.13
NATR's Price/Graham Number is ranked higher than
94% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.77 vs. NATR: 1.13 )
NATR' s 10-Year Price/Graham Number Range
Min: 0.66   Max: 4.13
Current: 1.13

0.66
4.13
Earnings Yield (Greenblatt) 8.50
NATR's Earnings Yield (Greenblatt) is ranked higher than
93% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. NATR: 8.50 )
NATR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 28.5
Current: 8.5

0.7
28.5
Forward Rate of Return (Yacktman) 13.85
NATR's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.33 vs. NATR: 13.85 )
NATR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -11.3   Max: 40.8
Current: 13.85

-11.3
40.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:LRLCY, KMB, RBGPY, EL, UNLRY » details
Natures Sunshine Products, Inc., was founded in 1972 and incorporated in Utah in 1976. The Company together with its subsidiaries is a natural health and Wellness Company primarily engaged in the manufacturing and direct selling of nutritional and personal care products. The Company sells its products to a sales force of independent Managers and Distributors who use the products themselves or resell them to other Distributors or customers. The Company markets its products worldwide. The Company has two reportable business segments that operate under the Nature's Sunshine Products brand and are divided based on their geographic operations in the United States and in countries outside the United States. The Company's third reportable business segment operates under the Synergy brand, which offers marketing plans, Distributor compensation plans and product formulations that are sufficiently different from those of NSP United States and NSP International to warrant accounting for these operations as a separate business segment. The Company has line of over 700 products includes several different product classifications, such as immunity, cardiovascular, digestive, personal care, weight management as well as other general health products. It purchase herbs and other raw materials in bulk and, after quality control testing, it formulate, encapsulate, tablet or concentrate them, and package them for shipment. Its products are manufactured at its facility in Spanish Fork, Utah. Contract manufacturers produce some of its vitamins, mineral and other nutritional supplements, personal care products and certain other miscellaneous products in accordance with its specifications and standards. The Company's independent Distributors market its products to customers through direct-selling techniques, as well as sponsoring other Distributors. Its products sold in the United States are shipped directly from its manufacturing and warehouse facilities located in Spanish Fork, Utah, as well as from its regional warehouses located in Georgia, Ohio and Texas. Its international operations maintain warehouse facilities with inventory to supply their customers. The Company's product lines by category includes; General health is a combination of assorted health products related to blood sugar support, bone health, cellular health, cognitive function, essential oils, joint health, mood, sexual health, sleep, sports and energy, and vision; Immunity line has been designed to offer products that support and strengthen the human immune system; Cardiovascular line has been designed to offer products that combine a variety of superior heart health ingredients to give the cardiovascular system optimum support; Disgestive line has been designed to offer products that regulate intestinal and digestive functions in support of the human digestive system; Personal care products for external use, including oils and lotions, aloe vera gel, herbal shampoo, herbal skin trea
» More Articles for NATR

Headlines

Articles On GuruFocus.com
Insider - no debt Mar 18 2013 
Nature's Sunshine CEO Resigns and Director Buys 365,000 Shares Mar 12 2013 
comment on NATR Nov 13 2012 
Is Nature’s Sunshine Breaking Through the Clouds? Mar 28 2012 

More From Other Websites
NATURES SUNSHINE PRODUCTS INC Financials Nov 15 2014
CORRECTING and REPLACING -- Nature's Sunshine Products Announces Special Shareholders Meeting Date Nov 12 2014
Nature’s Sunshine Products Announces Special Shareholders Meeting Date Nov 12 2014
Nature's Sunshine Products Announces Special Shareholders Meeting Date Nov 12 2014
NATURES SUNSHINE PRODUCTS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 10 2014
10-Q for Nature's Sunshine Products, Inc. Nov 08 2014
NATURES SUNSHINE PRODUCTS INC Files SEC form 10-Q, Quarterly Report Nov 06 2014
Nature's Sunshine Products Reports Third Quarter 2014 Financial Results Nov 05 2014
Nature’s Sunshine Products Names Richard Zhang and Henry Zhou as Managing Directors, China Nov 04 2014
Nature's Sunshine Products Names Richard Zhang and Henry Zhou as Managing Directors, China Nov 04 2014
Nature’s Sunshine Products to Announce Third Quarter 2014 Financial Results and to Host Conference... Oct 23 2014
Nature's Sunshine Products to Announce Third Quarter 2014 Financial Results and to Host Conference... Oct 23 2014
NATURES SUNSHINE PRODUCTS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Oct 14 2014
Nature's Sunshine Products Names Paul Noack as President of China and New Markets Oct 10 2014
Dr. Ingrum Bankston Joins Nature's Sunshine Products' Medical and Scientific Advisory Board Oct 07 2014
Dr. William J. Keller Appointed to Nature's Sunshine Products' Medical and Scientific Advisory Board Oct 02 2014
Dr. Nigel Gericke Joins Nature's Sunshine Products' Medical and Scientific Advisory Board Sep 30 2014
Research Finds That Melatonin May Aid Bone Strength, Creating New Customers for Nutrition Companies Sep 23 2014
Nature's Sunshine Products Announces Participation in Upcoming Investor Conferences Sep 11 2014
Dr. Sang Geon Kim Joins Nature's Sunshine Products' Medical and Scientific Advisory Board Sep 10 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK